D-0188-2025 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0188-2025 was initiated by Rising Pharma Holding, Inc. on Dec 30, 2024 and is designated Class II. Reason for recall: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: 42,527 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 15, 2025
Initiation Date
Dec 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
42,527 bottles

Product description

Duloxetine Delayed-Release Capsules USP 30 mg, a) 30 count (NDC 57237-018-30) and b) 1000 count (NDC 57237-018-99) bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ

Reason for recall

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Distribution pattern

Nationwide

Code information

a) Lot# DT3023051A, exp. date Apr-25; b) DT3023025A, exp. date Jan-25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0188-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0188-2025. Report a data issue: hello@regdatalab.com.